Ankur Pandya (@ankurfactorial) 's Twitter Profile
Ankur Pandya

@ankurfactorial

@[email protected]

ID: 107296071

linkhttps://www.hsph.harvard.edu/profile/ankur-pandya/ calendar_today22-01-2010 03:25:00

7,7K Tweet

5,5K Followers

2,2K Following

CEVR (@tuftscevr) 's Twitter Profile Photo

1/3: Thrilled to share topics/moderators for panel discussions at our upcoming 10/26 special symposium on #CEA: CEA’s Evolution: TBA Reflections on the Field: Ankur Pandya New Methods: Anirban Basu Policy Implications and Ideas: Sarah Emond The Future of CEA: Davene R. Wright, PhD

1/3: Thrilled to share topics/moderators for panel discussions at our upcoming 10/26 special symposium on #CEA:

CEA’s Evolution: TBA
Reflections on the Field: <a href="/AnkurFactorial/">Ankur Pandya</a>
New Methods: <a href="/Basucally/">Anirban Basu</a>
Policy Implications and Ideas: <a href="/sarahkemond/">Sarah Emond</a>
The Future of CEA: <a href="/WrightCensored/">Davene R. Wright, PhD</a>
Jinyi Zhu (@jinyizhu_) 's Twitter Profile Photo

So proud of our former RA Astrid Hanxuan (Astrid) Yu gearing up for an awesome talk at #SMDM24! Don’t miss her talk on how sampling distribution shapes meta-modeling! (Also, my talk is right before hers in the same session 😉)

Jinyi Zhu (@jinyizhu_) 's Twitter Profile Photo

🚨Thrilled to share our new JAMA Neurology publication! Building on previous work, we compare the past vs. future impact of stroke care improvements. Timely tPA drove 20 years of gains, but untapped potential lies in carotid imaging and broader tPA access. jamanetwork.com/journals/jaman…

Annals of Int Med (@annalsofim) 's Twitter Profile Photo

Study evaluates the conventional and distributional cost-effectiveness of prophylaxis with efanesoctocog alfa versus standard-care factor VIII (standard half-life and extended half-life) for patients living with severe hemophilia A in the United States. Read more at

Study evaluates the conventional and distributional cost-effectiveness of prophylaxis with efanesoctocog alfa versus standard-care factor VIII (standard half-life and extended half-life) for patients living with severe hemophilia A in the United States. Read more at